



[Home](#) / [Investors](#) / [News Releases](#)

# Insmmed to Host First Quarter 2019 Financial Results Conference Call on Tuesday, May 7, 2019

BRIDGEWATER, N.J., April 30, 2019 /[PRNewswire](#)/ -- Insmmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2019 financial results on Tuesday, May 7, 2019.

Insmmed management will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, May 7, 2019 to discuss the financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing (888) 317-6003 (domestic) or (412) 317-6061 (international) and referencing conference ID number 6243203. The call will also be webcast live on the company's website at [www.insmmed.com](http://www.insmmed.com).

A replay of the conference call will be accessible approximately one hour after its completion through May 14, 2019 by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and referencing replay access code 10131112. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at [www.insmmed.com](http://www.insmmed.com).

## About Insmmed

Insmmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmmed's first commercial product is ARIKAYCE<sup>®</sup> (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of *Mycobacterium avium* complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit [www.insmmed.com](http://www.insmmed.com).

## Contact:

Blaine Davis  
Insmmed Incorporated  
(908) 947-2841  
[blaine.davis@insmed.com](mailto:blaine.davis@insmed.com)

